Профилактика и лечение возвратных вирусных инфекций после ортотопической аллотрансплантации печени у больных циррозом печени HBV-и HCV-этиологии
Диссертация
История' ортотопической трансплантации печени (ОТП) берет начало • с 1 марта 1963 г., когда в г. Денвере (США) Tomas Starzl предпринял первую в мире попытку трансплантации печени у человека. С тех пор метод пережил разное к себе отношение. Исходно доминировал скепсис со стороны многих врачей к этой операции ввиду ее дороговизны, высокой летальности в-начальные годы внедрения. Постепенно… Читать ещё >
Содержание
- Список используемых сокращений
- Глава 1. Вирусные аспекты при трансплантации печени обзор литературы)
- 1. 1. Особенности течения НСУ-инфекции
- 1. 1. 1. Трансплантация печени при НСУ-инфекции
- 1. 1. 2. Иммуносупрессивная терапия при трансплантации печени по поводу НСУ-ассоциированного поражения печени
- 1. 1. 3. Лечение НСУ-инфекции до- и после трансплантации печени. Т
- 1. 2. Особенности течения НВУ-инфекции
- 1. 2. 1. Трансплантация печени при НВУ-инфекции
- 1. 2. 2. Профилактика инфицирования печеночного трансплантата вирусом гепатита В
- 1. 3. Герпесвирусная, цитомегаловирусная и Эпштейна-Барр вирусная инфекции и трансплантация печени
- 1. 1. Особенности течения НСУ-инфекции
- Глава 2. Материалы и методы исследования
- 2. 1. Характеристика больных, перенесших трансплантацию печени по поводу цирроза печени вирусной этиологии
- 2. 2. Методы исследования
- Глава 3. Оценка эффективности лечебно-профилактических мероприятий при НСУ-, НВУ- и НВУ/НБУ-инфекции и проявления инфекций герпесвирусной группы после трансплантация печени
- 3. 1. Клинический статус реципиентов печени, оперированных по поводу цирроза печени НВУ- и НВУ/НЕ)У-этиологии
- 3. 2. Особенности клинического течения посттрансплантационного периода у больных, оперированных по поводу цирроза печени НВУ- и НВУ/НОУ-этиологии
- 3. 3. Ведение больных, оперированных по поводу цирроза печени HBV- и HBV/HDV-этиологии, при различных вариантах профилактики инфицирования печеночного трансплантата вирусом гепатита В
- 3. 4. Клинический статус реципиентов печени, оперированных по поводу цирроза печени HCV-этиологии
- 3. 5. Особенности клинического течения посттрансплантационного периода у больных, оперированных по поводу цирроза печени HCV-этиологии
- 3. 6. Противовирусная терапия возвратной HCV-инфекции после трансплантации печени
- 3. 7. Проявления инфекций герпесвирусной группы после трансплантации печени
- Глава 4. Отдаленные результаты трансплантации печени при циррозе печени вирусной этиологии
- 4. 1. Отдаленные результаты трансплантации печени при циррозе печени HBV- и HBV/HDV-этиологии
- 4. 2. Отдаленные результаты трансплантации печени при циррозе печени HCV-этиологии
Список литературы
- Борисов, А.Е. Цирроз печени и портальная гипертензия / А. Е. Борисов, В. А. Кащенко // СПб.: Синтез Бук, 2009.-112с.
- Жебрун, А.Б. Вирусные гепатиты в Российской Федерации: аналитический обзор / А. Б. Жебрун // СПб.: НИИ эпидемиологии и микробиологии им. Пастера, 2000.-256с.
- Исаков, В.А. Герпесвирусная инфекция: рекомендации для врачей / В .А. Исаков, С. Б. Рыбалкин, М. Г. Романцов.- СПб., 2006.-96с.
- Львов, Д.К. Гепатит С / Д. К. Львов, И. В. Шахгильдян, П. Г. Дерябин //Медицинская вирусология.- М.: МИА, 2008.-С.483−489.
- Распространение генотипов вируса гепатита С в Санкт-Петербурге / Е. В. Эсауленко, Т. А. Ветров, Н. В. Дунаева и др. // Вирусные гепатиты.-2004.-№ 1 (19).-С.14−16.
- Реброва, О.Ю. Статистический анализ медицинских- данных. Применение пакета прикладных программ STATISTIC, А / О. Ю. Реброва.- М.: МедиаСфера, 2006.-312 с.
- Шахгильдян, И.В. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика) / И. В. Шахгильдян, М. И. Михайлов, Г. Г. Онищенко.- М.: ФГОУ ВУНМЦ Росздрава, 2003.-349с.
- A model to predict severe HCV-related disease following liver transplantation / M. Berenguer, J. Crippin, R. Gish et al. // J. Hepatology.-2003.-Vol.38.-№ 1.-P.34−41.
- A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B / R.P. Perrillo, T. Wright, J. Rakela et al. // J. Hepatology.-2001.-Vol.33.-P.424−432.
- A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation / J. Crippin, T. McCashland, N. Terrault et al. // Liver Transplant.-2002.-Vol.8.-№ 4.-P.350−355.
- A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation / E.J. Gane, S.K. Lo, S. M- Riordan et al. // J. Hepatology.-1998.-Vol.27.-№ 5.-P.1403−1407.
- A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis / P.W. Angus, S.J. Patterson, S.I. Strasser et al. //J. Hepatology.-2008.-Vol.48.-№ 5.-P.1460−1466.
- A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C / M. Angelico, A. Petrolati, R. Lionetti et al. // J. Hepatology.-2007.-Vol.46.-№ 6.-P.1009−1017.
- A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients / G. Davis, D. Nelson, N. Terrault et al. // Liver Transplant.-2005.-Vol.11.-№ 8.-P.941−949.
- Abbasoglu, O. Liver transplantation: Yesterday, today and tomorrow / O. Abbasoglu // World J. Gastroenterol.-2008.-Vol.l4.-№ 20.-P, 3117−3122.
- Adam, R. Liver Transplantation: The Current Situation / R. Adam, E. Hoti // Semin. Liver Dis.-2009.-Vol.29.-№ 1.-P.3−18.
- Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains / R. Kuwahara, R. Kumashiro, H. Inoue et al.'//Dig. Dis. Sci.-2004.-Vol.49.-P.300−303.
- Adefovir dipivoxil for the treatment of lamivudine-resistant Hepatitis B mutants / R. Perrillo, E.R. Schiff, E. Yoshida et al. // J. Hepatology.-2000.-Vol.32.-P.129−134.
- Adefovir dipivoxil therapy for lamivudine-resistant Hepatitis B in pre-and post liver transplantation patients / E.R. Schiff, C.-L. Lai, S .J. Hadziyannis et al. // J. Hepatology.-2003.-Vol.38.-P.1419−1427.
- Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation / R.H. Wiesner, E. Marin, M.K. Porayko et al. // Gastroenterol. Clin. North Am.-1993.-Vol.22.-№ 2.-P.351−366.
- Alter, H.J. Recovery, persistence, and sequelae in. hepatitis C virus infection: a perspective on long-term outcome / H.J. Alter, L.B. Seeff // Semin. Liver Dis.-2000.-Vol.20.-P. 17−35.
- Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors / A.M. Roque-Afonso, C. Feray, D. Samuel et al. // Gut.-2002.-Vol.50.-№k-P.95−99.
- Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients / T. Bizollon, S.N. Ahmed, S. Guichard et al. // Gut.-2000.-Vol.47.-№ 5.-P.698−702.
- Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation / X. Forns, M. Garcia-Retortillo, T. Serrano et al. // J. Hepatology.-2003.-Vol.39.-№ 3.-P.389−396.
- Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome / N. Selzner, E.L. Renner, M. Selzner et al. // Transplantation.-2009.-Vol.88.-P. 1214−1221.
- Applicability, tolerability and efficacy of preemptive anviral therapy in hepatitis C infected patients undergoing liver transplantation / A. Shergill, M. Khalili, K. Bollinger et al. // Am. J. Transplant.-2005.-Vol.5.-P. 118−124.
- Are posttransplantation protocol liver biopsies useful in the long term? / M. Berenguer, J.M. Rayon, M. Prieto et al. //Liver Transpl.-2001.-Vol.7.-P.790−796.
- Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation / M. Umeda, H. Marusawa, M. Ueda et al. //Am. J. Transplant.-2006.-Vol.6.-№ 11.-P.2680−2685.
- Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C / T. Bizollon, P. Pradat, J.Y. Mabrut et al. //Am. J. Transplant.-2005.-Vol.5.-P.1909−1913.
- Berenguer, M. Hepatitis C and transplantation / M. Berenguer, F.X. Lopez-Labrador, T.L. Wright// J. Hepatology.-2001.-Vol.35.-№ 5.-P:666−678.
- Berenguer, M. Natural history of recurrent hepatitis C / M. Berenguer // Liver Transpl.-2002.-Vol.8.-№ 10.-P.14−18^
- Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin / M. Berenguer // J. HepatoIogy.-2008.-Vol.49.-№ 2.-P.274−287.
- Brok, J. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane hepato-biliary group systematic review and meta-analysis of randomized trial / J. Brok, L.L. Gluud, C. Gluud //Am. J. Gastroenterol.-2006.-Vol.l01.-№ 4.-P.842−847.
- Brow, R.S. Hepatitis C and liver transplantation / R.S. Brow // Nature.-2005.-Vol.436.-P.973−978.
- Cahlin, C. Severe clinical course of de novo hepatitis B infection after liver transplantation / C. Cahlin, M. Olausson, S. Friman // Transplant. Proc.-2001.-Vol.33.-№ 4.-P.2467−2468.
- Castells, L. Hepatitis B vaccination in liver transplant candidates / L. Castells, R. Esteban//Eur. J. Gastroenterol. Hepatol.-2001.-Vol.l3.-№ 4.-P.359−361.
- Chou, S.W. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors / S.W. Chou // J. Infect. Dis.-1989.-Vol.l60.-№ 1.-P.ll-15.
- Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection / A. Grefte, M. Van der Giessen, W. Van Son, T.H. The // J. Infect. Dis.-1993.-Vol. 167.-№ 2.-P.270−277.
- Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation / I. Fernandez, J.C. Meneu, F. Colina et al. //Liver Transplant.-2006.-Vol.l2.-P.1805−1812.
- Clinical features of hepatitis B virus genotype A in Japanese patients / M. Kobajashi, Y. Arase, K. Ikeda et al. // J. Gastroenterol.-2003.-Vol.38.-P.656−662.
- Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation / L. Castells, V. Vargas, F. Rodriguez et al. // Liver Transplant.-2002.-Vol. 8.-№l 0.-P.892−900.
- Clinical reactivation after liver transplantation with anusual minor strain of hepatitis B virus in an accult carrier / B. Zoollner, H.H. Feucht, M. Sterneck et al. // Liver Transplant.-2006.-Vol.12.-P.1283−1289.
- CMV infection after organ transplantation: immunopathological and clinical" aspects / T.H. The, J.M. Grefte, W. van der Bij et al. // N. J. Med.-1994.-Vol.45.-№ 6.-P.309−318.
- CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis / N. Bonaros, B. Mayer, N. Schachner et al. // Clin. Transplant.-2008.-Vol.22.-№l.-P.89−97.
- Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B / P.W. Angus, G.W. McCaughan, E.J. Gane et al. // Liver Transplant.-2000.-Vol.6.-P.429−433.
- Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation / L. Castells, V. Vargas, H. Allende et al. // J. Hepatology.-2005.-Vol.43.-P.53−59.
- Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients / M. Berenguer, M. Prieto, F. San Juan et al. // J. Hepatology .-2002.-Vol.36 .-№ 1 .-P .202−210.
- Curry, M.P. Hepatitis B and hepatitis C viruses in liver transplantation / M.P. Curry // Transplantation.-2004.-Vol.78.-№ 7.-P.955−963.
- Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes / K. Watashi, M. Hijikata, M. Hosaka et al. // J. Hepatology.-2003 .-Vol.3 8.-P. 1282−1288.
- Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of sustained virological response after liver transplantation / R.J. Firpi, H. Zhu, G. Morelli et al. // Liver Transpl.-2006.-Vol.l2.-P.51−57.
- Cytomegalovirus hepatitis in liver transplantation: Prospective analysis of 93 consecutive orthotopic liver transplantations / C.V. Paya, P.E. Hermans, R.H. Wiesner et al. // J. Infect. Dis.-1989.-Vol.l60.-№ 5.-P.752−758.
- Cytomegalovirus infection of the orthotopic liver transplantation is restricted by a pre-existing antiviral immune response of the recipient / A.L. Bissinger, H. Oettle, G. Jahn et ah. // J. Med. Virol.-2004.-Vol.73.-№ 1 .-P.45−53.
- Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C / H.R. Rosen, S. Chou, C.L. Corless et al. // Transplant.-1997.-Vol.64.-№ 5.-P.721−726.
- Daily interferon therapy for hepatitis C virus infection in liver transplant recipients / S J. Cotler, D.R. Ganger, S. Kaur et al. // Transplantation.-2001 .-Vol.71 .-№ 2.-P.261−266.
- De novo and apparent de novo hepatitis B virus infection after liver transplantation / B. Roche, D. Samuel, M. Gigou et al. // J. Hepatology.-1997.-Vol.26.-№ 3.-P.517−526.
- De novo hepatitis B infection after liver transplantation: sources of disease, incidence and impact / R. Fabia, M. Levy, J. Crippin et al. // Liver Transpl. Surg.-1998.-Vol:4.-№ 2.-P.l 19−127.
- Definition of a subset of human peripheral blood mononuclear cells, that are permissive to human cytomegalovirus infection / C. Soderberg, S. Larsson, S. Bergstedt-Lindqvist, E. Moller // J. Virol.-1993.-Vol.67.-№ 6.-P.3166−3175.
- Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors / T. Laskus, L.F. Wang, J. Rakela et al. // Virology.-1996.-Vol.220.-№ 1 .-P. 171 -176.
- Early development of chronic active hepatitis C virus infection after liver transplantation association with treatment of rejection / M. Berenguer, M. Prieto, J. Cordoba etal. //J. Hepatology.-1998.-Vol.28.-№ 5.-P.756−763.
- Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation / R.T. Stravitz, M.L. Shiffman, AJ. Sanyal et al. // Liver Transpl.-2004.-Vol.l0.-P.850−858.
- Efficacy and safety of entecavir and lamivudine in compensated cirrhotic patients wifh chronic hepatitis B / E.R. Schiff, W.M. Lee, Y.C. Chao et al. // Hepatology.-2005.-Vol.42.-P.583−584.
- Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study / J.A. Carrion, M. Navasa, M. Garcira-Retortillo et al.'// Gastroenterology.-2007.-Vol.l32.-P.1746−1756.
- Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C / M. Berenguer, A. Palau, A. Fernandez et al. //Liver Transpl.-2006.-Vol.l2.-P.1067−1076.
- Estimating future hepatitis C morbidity, mortality, and costs in the United States / J.B. Wong, G.M. McQuillan, J.G. McHutchison et al. // Am. J. Public. Health.-2000.-Vol.90.-P. 1562−1569.
- Evaluation of the effect of immunosuppressive agents on hepatitis C: cyclosporine reduces viral replication in the replicon model / T. Manire, C. Ethier, V.A. Raymond et al. // Transplantation.-2004.-Vol.78.-№ 1.-P.13−14.
- Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation / R. Segovia, A. Sanchez-Fueyo, A. Rimola et al. // Liver Transplant.-2001.-Vol.7.-P.106−112.
- Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients / R. Dupuis, M. Harris, K. Gillis et al. // Transpl. Proceedings.-2007.-Vol.39.-№ 10.-P.3266−3270.
- Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis / M. Angelico, D. DiPaolo, M.O. Trinito et al. // Hepatology.-2002.-Vol.35.-№ 1 .-P. 176−181.
- Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation / P. Toniutto, E. Fumo, M. Caldato et al. // Transplantation.-2004.-Vol.77.-№ 3.-P.472−473.
- Fibrosis progression after liver transplantation in patients with recurrent hepatitis C / U.P. Neumann, T. Berg, M. Bahra et al. // J. Hepatology.-2004.-Vol.41.-№ 5.-P.830−836.
- Fibrosis progression in hepatitis C positive liver recipients after sustained virologie response to antiviral combination therapy (interferon-ribavirin therapy) / M. Bahra, U.P. Neumann, D. Jacob et al. // Transplantation.-2007.-Vol.83.-P.351−353.
- Four year assessment of entecavir resistance in nucleoside-nave and lamivudine-refractory patients / R.J. Colonno, R.E. Rose, C.J. Pokornowski et al. // J. Hepatology .-2007.-Vol.46.-Suppl. 1 .-P.294.
- Genotypes and clinical phenotypes of* hepatitis B virus in patients with chronic hepatitis B virus infection / J.H. Kao, P.J. Chen, M.Y. Lai, D.S. Chen // J. Clin. Microbiol.-2002.-Vol.40.-P. 1207−1209.
- Global epidemiology of hepatitis B virus / B. Custer, S.D. Sullivan, T.K. Hazlet et al. // Clin. Gastroenterol.-2004.-Vol.38:-Suppl.l0.-P.158−168.
- Griffiths, P.D. Viral complications after transplantation / P.D. Griffiths // J: Antimicrob. Chemother.-1995.-Vol.36.-Suppl.B.-P.91 -106.
- HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C / C.T. Wai, C.J. Chu, M. Hussain et al. // Hepatology.-2002.-Vol.36.-№ 6.-P. 1425−1430.
- HCV recurrence in living- donor liver transplantation / M. Taniguchi, M. Wachs, T. Bak et al. //Am. J. Transplant.-2002.-Vol.3.-Suppl.-A4.
- HCV-related fibrosis progression following liver transplantation: increase in recent years / M. Berenguer, L. Ferrell, J. Watson et al. // J. Hepatology.-2000.-Vol.32.-№ 4.-P.673−684.
- Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation / M. Garcia-Retortillo, X. Forns, J.M. Llovet et al. // J. Hepatology.-2004.-Vol.40.-№ 3.-P.699−707.
- Hepatitis C viral infection in liver transplantation / M.W. Johnson, W.K. Washburn, R.B. Freeman et al. //Arch. Surg.-1996.-Vol.l31.-P.284−291.
- Hepatitis C virus re-infection: new perspectives / M.F. Sprinzl, G. Otto, P.R. Galle, M. Schuchmann// Clin. Transplant.-2006.-Vol.20.-Suppl.l7.-P.l 17−123.
- Herpes simplex virus hepatitis after solid organ transplantation in adults / S. Kusne, M. Schwartz, M.K. Breinig et al. // J. Infect. Dis.-1991.-Vol. 163 .-P. 10 011 007.
- Heterogeneity of hepatitis C virus genotype 4. strains circulatingin southwestern France / F. Nicot, F. Legrand-Abravanel, F. Sandres et al. // J. Gen. Virol.-2005.-Vol.86.-№ 1.-P.107−114.
- HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation / M. Harma, K. Hockerstedt, O. Lyytikainen, I. Lautenschlager // J. Med. Virol.-2006.-Vol.78.-№ 6.-P. 800−805.
- High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation / D. Mutimer, D. Pillay, E. Dragon et al. // J. Hepatology.-1999.-Vol.30.-P.715−721.
- High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection / W.J. Su, M.C. Ho, Y.H. Ni et al. // J. Pediatr. Gastroenterol. Nutr.-2009.-Vol.48.-№ 2.-P.203−208.
- Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation / T. Bizollon, P. Pradat, J.Y. Mabrut et al. //Am. J. Transplant.-2007.-Vol.7.-P.448−453.
- Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens / J. Hunt, F.D. Gordon, W.D. Lewis etal. //Liver Transpl.-2001.-Vol.7.-P.1056−1063.
- Histology predict cirrhotic evolution of post transplant hepatitis C / M. Guido, S. Fagiuoli, G. Tessari et al. // Gut.-2002.-Vol.50.-№ 5.-P.697−700.
- Holguin, K. Drug Cocktail Prevents Hepatitis B Virus from recurring after liver transplant / K. Holguin // Annals of Surgery.-2002.-Vol.5.-№ 310.-P.794−797.
- Homotransplantation of the liver in humans / T.E. Starzl, T.L. Marchioro, K.N. Von Kaaulla et al. // Surgery, Gynecology and Obstetrics.-1963.-Vol.117.-P.659−676.
- Hoofnagle, J.H. The treatment of chronic viral hepatitis / J.H. Hoofnagle, A.M. Bisceglie // N. Engl. J: Med.-1997.-Vol.336.-P.347−356.
- Humar, A. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance / A. Humar, K. Washburn, R. Freeman // Liver Transpl.-2007.-Vol.l3.-№ 10.-P.1422−1427.
- Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection / S.M. Aalto, K. H. Linnavuori, H. Peltola et al. // J. Med. Virol.-1998.-Vol.56.-№ 3.-P.186−191.
- Immunosuppressive activity of ribavirin using the rabbit skin allograft model / W.B. Jolley, T.W. Call, L.S. Alvord, D.B. Hinshaw // Ann. N.Y. Acad. Sci.-1977.-Vol.284.-P.230−232.
- Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation^ for hepatitis C / K. Burak, W. Kremers, K. Batts et al. // Liver Transpl.-2002.-Vol.8.-№ 4.-P.362−369.
- Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV allografts / A.P. Khapra, K. Agarwal, M.I. Fiel et al. // Liver Transpl.-2006.-Vol.l2.-№ 10.-P.1496−1503.
- Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection / B.J. Veldt, J.J. Poterucha, K.D. Watt et al. //Am. J. Transplant.-2008.-Vol.8.-P.2426−2433.
- Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization / R.W. McGory, M.B. Ishitani, W.M. Oliveira et al. // Transplantation.-1996.-Vol.61.-№ 9.-P.1358−1364.
- Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation / C. Feray, M. Gigou, D. Samuel et al. //Ann. Intern. Med.-1998.-Vol.128.-P.810.
- Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors / P.J. Gaglio, S. Malireddy, B.S. Levitt et al. // Liver Transplant.-2003 .-Vol.9. -№ 10.-P. 1028−103 5.
- Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease / T. Steinmuller, D. Seehofer, N. Rayes et al. // J. Hepatology.-2002.-Vol.35 .-P. 1528−153 5.
- Increasing serum levels of Ig M anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares / P. Ciccorossi, F. Filipponi, F. Oliveri et al. // J. Viral Hepat.-2003.-Vol.l0.-№ 3.-P.168−173.
- Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation / R.M. Thomas, J.J. Brems, G. Guzman-Hartman et al. // Liver Transplant.-2003.-Vol.9.-P.905−915.
- Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on Fas mediated apoptosis after liver transplantation for hepatitis C / V. Di Martino, C. Brenot, D. Samuel et al. // Transplantation.-2000.-Vol.70.-№ 9.-P.1390−1396.
- Interferon-a2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study / D. Samuel, T. Bizollon, C. Feray et al. // Gastroenterology.-2003.-Vol.l24.-P.642−650.
- Interferon-alpha for profilaxis of recurrent viral hepatitis C in liver transplant recipients / N. Singh, T. Gayowski, C. Wannstedt et al. // Transplantation.-1998.-Vol.65.-№l.-P.82−86.
- Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis / C.S. Wang, H.H. Ko, E.M. Yoshida etal. //Am. J. Transplant.-2006.-Vol.6.-P.1586−1599.
- Jiang, L.S. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation / L.S. Jiang, N.S. Cheng, L.N. Yan // World. J. Gastroenterol.-2009.-Vol.28.-№ 15 (20).-P.2489−2499.
- Kao, J.H. Hepatitis B viral genotypes: Clinical relevance and molecular characteristics / J.H. Kao // J. Gastroenterohepatol.-2002.-Vol.l7.-P.643−650.
- Kidd-Ljunggren, K. Clinical and serological variation between patients infected with different hepatitis B virus genotypes / K. Kidd-Ljunggren, E. Myhre, J. Blackberg // J. Clin. Microbiol.-2004.-Vol.42.-№ 12.-P.5837−5841.
- Kidd-Ljunggren, K. Genetic variability in hepatitis B viruses / K. Kidd-Ljunggren, Y. Miyakawa, A.H. Kidd // J. G. Virology.-2002.-Vol.83.-P. 1267−1280.
- Kim, W.R. The burden of hepatitis C in the United States / W.R. Kim // Hepatology.-2002.-Vol.36.-P.30−34.
- Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection / R.J. Firpi, D.R. Nelson, G.L. Davis et al. // Liver Transpl.-2003.-Vol.9.-P.57.
- Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation / S.F. Dodson, M.E. de Vera, C.A. Bonham et al. //Liver Transplant.-2000.-Vol.6.-P.434−439.
- Lamivudine as First- and second-line treatment of hepatitis B infection after liver transplantation / D. Seehofer, N. Rayes, T. Berg et al. // Transplant. Int.-2000.-Vol.l3.-P.290−296.
- Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study / J.L. Limquiaco, J. Wong, V.W. Wong et al. // J. Med. Virol.-2009.-Vol.81.-№ 2.-P.224−229.
- Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation / E.J. Gane, P.W. Angus, S. Strasser et al."// Gas troenterology.-2007.-Vol.132.-№ 3.-P.931−937.
- Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis / L. Grellier, D. Mutimer, M. Ahmed et al. // Lancet.-1996.-Vol.348.-№ 9036.-P.1212−1215.
- Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B / J.P. Villeneuve, L.D. Condreay, B. Willems et al. // J. Hepatology.-2000.-Vol.31.-P.207−210.
- Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up / D. Mutimer, G. Dusheiko, C. Barrett et al. // Transplantation.-2000.-Vol.70.-№ 5.-P.809−815.
- Late onset cytomegalovirus disease in liver transplant recipients—de novo reactivation in recurrent hepatitis C virus hepatitis / N. Singh, A. Zeevi, T. Gayowski, I. R: Marino // Transplant. Int.-1998.-Vol. 11 .-№ 4.-P.308−311.
- Lauchart, W. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts / W. Lauchart, R. Muller, R. Pichlmayr // Transplant. Proc.-1987.-Vol.l9.-№ 5.-P.4051−4053.
- Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation / Y. Ueda, Y. Takada, H. Haga et al. //Transplantation.-2008.-Vol.85.-P.855−862.
- Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine / C. Lo, C. Li, G. Lau et al. // Liver Transplant.-2005.-Vol.l 1.-P.807−803.
- Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period / D.G. Farmer, D.M. Anselmo, R.M. Ghobrial etal. //Ann. Surg.-2003.-Vol.237.-№ 5.-P.666−675.
- Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients / G. Testa, J.S. Crippin, G.J. Netto et al. // Liver Transplant. Surg.-2000.-Vol.6.-№ 5.-P.553−561.
- Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis / C.M. Lo, S.T. Cheung, C.L. Lai et al. // Ann. Surg.-2001.-Vol.233.-P.276−281.
- Liver transplantation in European patients with the hepatitis B surface antigen / D. Samuel, M. Muller, G. Alexander et al. // N. Engl. J. Med.-1993.-Vol.329.-P. 1842−1847.
- Lok, A.S. Management of hepatitis B: 2000-summary of a workshop / A.S. Lok, E.J. Heathcote, J.H. Hoofhagle // Gastroenterology.-2001.-Vol.l20.-№ 7.-P.1828−1853.
- Longer survival of liver transplant recipients with hepatitis virus coinfections / K. Rifai, H. Wedemeyer, J. Klempnauer et al. // J. Clin. Virol.-2006.-Vol.36.-Suppl.2.-P. 180.
- Longitudinal study of human herpesvirus 6 infection in organ transplant recipients / G. Herbein, J. Strasswimmer, M. Altieri et al. // Clin. Infect. Dis.-1996.-Vol.22.-№l.-P.171−173.
- Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact / T. Walter, J.Y. Scoazec, O. Guillaud et al. //Liver Transpl.-2009.-Vol. 15.-P.54−63.
- Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection / A. Kuo, V. Tan, B. Lan et al. // Liver Transpl.-2008.-Vol.14.-P. 1491−1497.
- Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up / U.P. Neumann, T. Berg, M. Bahra et al. // Transplantation.-2004.-Vol.77,-№ 2.-P.226−231.
- Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression / R. Lionetti, G. Tisone, G. Palmieri et al. // Dig. Liver Dis.-2010.-Vol.42.-№ 4.-P.297−303.
- Management of hepatitis C virus in special populations: patient and treatment considerations / R.G. Gish, N.H. Afdhal, D.T. Dieterich, K.R. Reddy // Clin. Gastroenterol. Hepatol.-2005.-Vol.3.-P.311−318.
- Might Rapid Virological Response Be Used as a Stopping Rule in Liver Transplant Recipients Treated with Pegylated Interferon Plus Ribavirin? / M. Donato, F. Agnelli, C. Rigamonti etal. //Liver transplantation.-2008.-Vol, 14.-P.1383−1384.
- Moeller, M. Impact of length of therapy and predictive value models on SVR in HCV patients post OLT / M. Moeller, G. Divine, K.A. Brown // J. Hepatology.-2009.-Vol.50.-P.391.
- Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation / E. Drouet, R. Colimon, S. Michelson et al. // J. Clin. Microbiol.-1995.-Vol.33.-№ 2.-P.389−3 94.
- Nair, S. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation / S. Nair, J. Lipscomb, J. Eason // Transplantation.-2008.-Vol.86.-P.418−422.
- Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation / M. Berenguer, M. Prieto, J.M. Rayon et al. // Hepatology.-2000.-Vol.32.-№.4.-P.852−858.
- Older donor livers show early histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C / S.C. Rayhill, Y.M. Wu, D.A. Katz et al. // Transplantation.-2007.-Vol.84.-№ 3 .-P.331 -339.
- Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts / H.E. Vargas, T. Laskus, L.F. Wang et al. // Gastroenterology.-1999.-Vol. 117.-№ 1 .-P. 149−153.
- Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation / M.S. Cattral, A.W. Hemming, I.R. Wanless et al. // Transplantation.-1999.-Vol.67.-№ 9.-P. 1277−1280.
- Outcome of orthotopic liver transplantation in patients with hepatitis C / S.W. Paik, H.P. Tan, A.S. Klein et al. // Dig. Dis. Sci.-2002.-Vol.47.-P.450−455.
- Passive immunoprophylaxis after liver transplantation in HBs-Ag-positive patients / D. Samuel, A. Bismuth, D. Mathieu et al. // Lancet.-1991.-Vol.337.-P.813−815.
- Patterns of hepatitis delta virus reinfection and disease in liver transplantation1/ A. Ottobrelli, A. Marzano, A. Smedile et al. // Gastroenterology.-1991.-Vol. 101.-P.T 649−1655.
- Patterson, S.J. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos (t)ide analogues. / S.J. Patterson, P.W. Angus // Current opin. organ. transplant.-2009i-Vol.l4.-P:225−230.
- Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled, trials V N. Chalasani, C. Manzarbeitia, P. Ferenci et.al. // Hepatology.-2005.-Vol.4 l.-№ 2.-P.289−298.
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial / M.P. Manns, J.G. McHutchison, S.C. Gordon et al. //Lancet.-2001.-Vol.358.-№ 9286.-P.958−965.
- Pegylated interferon induced immune-mediated hepatitis post-liver transplantation / N. Kontorinis, K. Agarwal, N. Elhajj et al. // Liver Transpl.-2006.-Vol.12.-P.827−830.
- Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation / S. Dinges, I. Morard, M. Heim et al. // Transpl. Infect. Dis.-2009.-Vol.ll.-P.33−39.
- Petrovic, Early recurrence of hepatitis C virus infection after liver transplantation /L.M. Petrovic //Liver Transpl.-2006.-Vol.l2.-№ 1 l.-Suppl.2.-P.32−37.
- Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation / T. Bizollon, U. Palazzo, C. Ducerf et al. // J. Hepatology.-1997.-Vol.26.-№ 2.-P.500−504.
- Predictors of patient and graft survival following liver transplantation for hepatitis C / M. Charlton, E. Seaberg, R. Wiesner et al. // J. Hepatology.-1998.-Vol.28.-№ 3.-P.823−830.
- Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation / M. Cescon, G.L. Grazi, A. Cucchetti et al. // Liver Transpl.-2009:-Vol.l5.-P.782−789.
- Preemptive therapy for hepatitis C virus after living-donor liver transplantation / Y. Sugawara, M. Makuuchi, Y. Matsui et al. // Transplantation.-2004.-Vol.78.-P.1308−1311.
- Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation./ M. Hussain, C. Soldevila-Pico, S. Emre et al. // Liver Transpiant.-2007.-Vol.l3.-№ 8:-P.l 137−1144.
- Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers / R. Barcena, G. Moraleda, J. Moreno et al. // World J. Gastroenterol.-2006.-Vol.l2.-№ 13.-P.2070−2074.
- Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination / M. Barcena, F. Garcia-Hoz, M. Vazquez Romero et al. //Am. J. Gastroenterol.-2002.-Vol.97.-№ 9.-P.2398−2401.
- Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis / S. Zheng, Y. Chen, T. Liang et al. // Liver Transpl.-2006.-Vol.l2.-P.253−258.
- Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment / V. Mazzaferro, A. Tagger, M. Schiavo et al. // Transplant. Proc.-2001 .-Vol.33 .-P. 1355−1357.
- Prognosis of chronic hepatitis C: results of a large, prospective cohort study / C. Niederau, S. Lange, T. Heitges et al. // J. Hepatology.-1998.-Vol.28.-P.1687−1695.
- Prognostic significance and risk factors of untreated cytomegalovirus viremia In liver transplant recipients / A.D. Badley, R. Patel, D.F. Portela et al. // J. Infect. Dis.-1996.-Vol. 173.-№ 2.-P.446−449.
- Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation / P.W. Baron, D. Sindram, D. Higdon et al. //Liver Transpl.-2000.-Vol.6.-№ 4.-P.407−412.
- Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation / S. Karademir, H. Astarcioglu, M. Akarsu et al. // Transplant. Proc.-2006.-Vol.38.-№ 2.-P.579−583.
- Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin / J.S. Markowitz, P. Martin, A.J. Conrad et al. // J. Hepatology.-1998.-Vol.28.-№ 2.-P.585−589.
- Prophylaxsis Against Recurrance of Hepatitis B Virus After Liver Transplantation: A Retrospective Analysis Spanning 20 Years / N. Yilmaz, M.L. Shiffman, R. Todd Stravitz et al. // J. Liver Int.-2008.-Vol.28.-№l.-P.72−78.
- Rapid and severe early HCV recurrence following adult living donor liver transplantation / R.M. Ghobrial, F. Amersi, D. Farmer et al. // Am. J. Transplant.-2002.-Vol.3.-A104.
- Razonable, R.R. Cytomegalovirus infection after liver transplantation: Current concepts and challenges / R.R. Razonable // World J. Gastroenterol.-2008.-Vol. 14.-№ 31 .-P.4849−4860.
- Recurrence of hepatitis B and hepatitis D after orthotopic liver transplantation / M. Lucey, D. Graham, P. Martin et al. // Gut.-1992.-Vol.33.-P. 1390−1395v.
- Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil / G.G. Fasola, G.J. Netto, L.W. Jennings et al.7/ Transplant. Proc.-2002.-Vol.34.-P. 1563.
- Recurrence of hepatitis D in liver transplants / E. David, J. Rahier, A. Pucci et al. // Gastroenterology.-1993.-Vol.l04.-P.l 122−1125.
- Recurrent Hepatitis C after Liver Transplantation: On-Treatment Prediction of Response to Peginterferon/Ribavirin Therapy / I.A. Hanouneh, G. Miller, F. Aucejo et al. // Liver Transpl.-2008.-Vol.l4.-P.53−58.
- Recurrent hepatitis G after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin / J. Ahmad, S.F. Dodson, A.J. Demetris et aL. // Liver Transplant.-2001.-Vol.7.-№ 10.-P.863−869.
- Report of the monothematic EASE / D. Samuel, X. Forns, M. Berenguer et al. [Conference on liver transplantation for viral hepatitis, Paris, France, 12−14 January, 2006]j//J. Hepatology.-2006.-VoM5.-№L-PT27-l:43-
- Response to antiviral therapy in. liver transplant recipients with-recurrent hepatitis-C: viral infection: a>single center experience / A. Jain, R. Sharma, C. Ryan et al. // Clin. Transplant.-2010.-Vol.24.-P. 104−111.
- Risk factors for hepatocellular carcinoma among patients with chronic liver disease/H. Tsukuma, T. Hiyama, S. Tanaka et al. //N. Engl. J. Med.-1993.-Vol.328.-P. 1797−1801.
- Saltzman- R.L. Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia / R.L. Saltzman, M.R. Quirk, M.C. Jordan//J. Clin. Investig.-1988.-Vol.81.-№l.-P.75−81.
- Sanchez-Fueyo, A. Hepatitis B vaccination after liver transplantation / A. Sanchez-Fueyo, E. Martinez-Bauer, A. Rimola // J. Hepatology.-2002.-Vol.36.-P.257−258.
- Schrier, R.D. Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection / R.D. Schrier, J.A. Nelson, M.B. Oldstone // Science.-1985.-Vol.230.-№ 4729.-P. 1048−1051.
- Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease / D.H. Dockrell, J. Prada, M.F. Jones et al. // J. Infect. Dis.-1997.-Vol.l76.-№ 5.-P.l 135−1140.
- Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation / P.A. Sheiner, M.E. Schwartz, E. Mor et al. // J. Hepatology.-1995.-Vol.21.-P.30−34.
- Sia, I.G. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients / I.G. Sia, R. Patel // Clinic. Microbiol. Reviews.-2000.-Vol.l3.-№l.-P.83−121.
- Singh, N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients / N. Singh // Clinic. Infect. Dis.-2001.-Vol.32.-№ 5.-P.742−751.
- Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation / S. Brillanti, M. Vivarelli, N. De Ruvo et al. // Liver Transplant.-2002.-Vol.8.-№ 10.-P.884−888.
- Specific inhibition of hepatitis C virus replication by cyclosporin A / M. Nakagawa, N. Sakamoto, N. Enomoto et al. // Biochem. Biophys. Res. Commun.-2004.-Vol.313.-P.42−47.
- Steroid-free liver transplantation, using rabbit antithymocyte globulin and early tacrolimus monotherapy / J. Eason, S. Nair, A. Cohen et al. // Transplantation.-2003.-Vol.75.-№ 8.-P. 1396−1399.
- Sun, H-Y. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review / H-Y. Sun, M.M. Wagener, N. Singh // Am. J. Transpl.-2008.-Vol.8.-№ 10.-P.2111−2118.
- Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence / P. Sharma, J.A. Marrero, R.J. Fontana et al. // Liver Transpl.-2007.-Vol. 13.-P. 1100−1108.
- Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation / F.P. Picciotto, G. Tritto, A.G. Lanza et al. // J. Hepatology.-2007.-Vol.46.-P.459−465.
- Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation / D.E. Eckhoff, B.M. McGuire, L.R. Frenette et al. // Transplantation.-1998.-Vol.65.-№ 2.-P.180−187.
- Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence / L. Belli, A. Alberti, M. Vangeli et al. // Liver Transplant.-2003.-Vol.9.-№ 2.-P.201−202.
- Terrault, N.A. Treating hepatitis C infection in liver transplant recipients / N.A. Terrault, M. Berenguer // Liver Transpl.-2006.-Vol.l2.-P.l 192−1204'.
- The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C / T. Ikegami, A. Taketomi, Z. Soejima et al. // Transplant. Proct.-2009.-Vol.41.-P.4246−4252.
- The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient / D.D. Douglas, J. Rakela, T.L. Wright et al. // Liver Transplant. Surg.-1997.-Vol.3.-№ 2.-P.105-l 11.
- The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C / R. Idilman, M.N. De, A. Colantoni et al. // Am. J. Gastroenterol.-2002.-Vol.97.-P.435−439.
- The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation / P.A. Sheiner, P. Boros, F.M. Klion et al. // J. Hepatology.-1998.-Vol.28.-P.831−838.
- The prevalence and genetic diversity of hepatitis C infection in antenatal, clinic attenders in two regions of England / M.A. Balogun, M.E. Ramsay, J.V. Parry et al. //Epidemiol. Infect.-2000.-Vol.l25.-№ 3.-P.705−712.
- The risk of transmission of hepatitis B from HBsAg (-), HBcAb (+), HBIgM (-) organ donors / M.E. Wachs, W.J. Amend, N.L. Ascher et al. // Transplantation.-1995.-Vol. 5 9.-№ 2.-P.2304−2314.
- Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report / K.K. Kim, K.N. Kim, S. Hwang et al. //Korean. J. Gastroenterol.-2005.-Vol.45.-№ 3.-P.174−180.
- Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen / R.C. Dickson, J.E. Everhart, J.R. Lake et al. // Gastroenterology.-1997.-Vol. 113 .-№ 5.-P. 1668−1674.
- Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplantats / S. Uemoto, K. Sugiyama, H. Marusawa et al. // Transplantation.- 1998.-Vol.65. -№ 4 .-P.494−499.
- Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy / G. Everson, J. Trotter, L. Forman et al. // J. Hepatology.-2005.-Vol.42.-№ 2.-P.255−262.
- Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants / M.D. Sawyer, J.L. Mayoral, K.J. Gillingham et al. // Arch. Surg.-1993.-Vol.l28.-№.2.-P. 165−170.
- Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States / P.J. Thuluvath, K.L. Krok, D.L. Segev, H.Y. Yoo // Liver Transpl.-2007.-Vol.l3.-P.719−724.
- Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation, with particular reference to hepatitis C virus / A. Marcos, B. Eghtesad, J. Fung et al. // Transplantation.-2004.-Vol.78.-№ 7.-P.966−971.
- Use of OKT3 is associated with-early and sever recurrence of hepatitis C after liver transplantation / H.R. Rosen, C.R. Shackleton, L. Higa et al. // Amer. J. Gastroenterol.-1997.-Vol.92.-№ 2.-P. 1453−1457.
- Validation and refinement of survival models for liver retransplantation / H. Rosen, M. Prieto, T. Casanovas-Taltavull et al. // J. Hepatology.-2003 .-Vol.38.-№ 2.-P.460−469.
- Virologie response and resistance to adefovir in patients with chronic Hepatitis B / S.K. Fung, H.B. Chae, R.J. Fontana et al. // J. Hepatology.-2006.-Vol.44.-P.283−290.
- WallJ W. Retransplantation" for recurrent hepatitis C: the argument against / W. Wall, A. Khakhar // Liver Transplant.-2003.-Vol.9.-№ 11 .-Suppl.-P.73−78.
- Wang, Y.M. Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the Nacional University Hospital of Singapore / Y.M. Wang, W.C. Ng, S.K. Lo//J. Gastroenterol'.- 1999.-Vol.34.-P.481−485.
- Wiesner, R. Report of the first International liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C / R. Wiesner, M. Sorrell, F. Villamil // Liver Transplant.-2003.-Vol.9.-№ll.-Suppl.-P.l-9.
- Yachimski, P. Hepatitis B Virus Infection in Liver Transplant Candidates and Recipients / P. Yachimski, R. Chung // Medscape General Medicine.-2005.-Vol.7.-№ 2.-P.20.
- Yao, F.Y. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection / F.Y. Yao, N.M. Bass // J. Hepatology.-2000.-Vol.33.-P.301−307.
- Zein, N.N. Clinical significance of hepatitis C viral genotypes / N.N. Zein // Clin. Microbiol. Rev.-2000.-Vol.l3.-P.223−235.223 <